CAJ | 학술논문

顺铂联合氟尿嘧啶仍是晚期食管痛的基本治疗方案;新的细胞毒药物如紫杉醇类、拓扑异构酶抑制剂及新联合方案是研究的热点;奥沙利铂可替代顺铂,口服氟尿嘧啶衍生物可替代静脉氟尿嘧啶治疗晚期食管癌;二线治疗研究已逐渐被接受和增多;分子靶向治疗将为食管癌提供更多、更好的选择.
순박연합불뇨밀정잉시만기식관통적기본치료방안;신적세포독약물여자삼순류、탁복이구매억제제급신연합방안시연구적열점;오사리박가체대순박,구복불뇨밀정연생물가체대정맥불뇨밀정치료만기식관암;이선치료연구이축점피접수화증다;분자파향치료장위식관암제공경다、경호적선택.
Cisplatin in combination with fluorouracil still is considered as the basic therapeutic scheme for advanced esophageal cancer. New cytotoxic drugs, such as taxanes and topoisomerase inhibitor etc, and new regimens are focus researches for medical treatment. Intravenous fluorouracil can be replaced by oral fluorouracil derivative, and cisplatin can be replaced by oxaliplatin in the regimens of contained cisplatin and fluorouracil for advanced esophageal cancer. Patients with advanced esophageal cancer are now offered seconded line treatment, and the number of research protocols is increasing. Molecule targeted therapy as a promising treatment will provide more and better options for patients.